These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28725989)

  • 21. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement.
    Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM
    Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
    Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
    N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
    Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
    Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
    Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
    Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
    Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.
    Metzgeroth G; Schwaab J; Naumann N; Jawhar M; Haferlach T; Fabarius A; Hochhaus A; Hofmann WK; Cross NCP; Reiter A
    Blood Adv; 2020 Feb; 4(3):440-443. PubMed ID: 31995156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
    Savage N; George TI; Gotlib J
    Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.
    Bidet A; Chollet C; Gardembas M; Nicolini FE; Genet P; Delmer A; Caillot D; Dulucq S; Mahon FX; Lippert E
    Br J Haematol; 2018 Jul; 182(1):148-152. PubMed ID: 28485070
    [No Abstract]   [Full Text] [Related]  

  • 33. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications.
    Gupta SK; Jain N; Tang G; Futreal A; Wang SA; Khoury JD; Yang RK; Fang H; Patel KP; Luthra R; Routbort M; Barkoh BA; Chen W; Mao X; Zhang J; Medeiros LJ; Bueso-Ramos CE; Loghavi S
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1300-1304. PubMed ID: 33022638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis.
    Patnaik MM; Lasho TL; Finke CM; Pardanani A; Tefferi A
    Am J Hematol; 2016 Mar; 91(3):E12-4. PubMed ID: 26662677
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).
    Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A
    Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
    Di Giacomo D; Quintini M; Pierini V; Pellanera F; La Starza R; Gorello P; Matteucci C; Crescenzi B; Fiumara PF; Veltroni M; Borlenghi E; Albano F; Forghieri F; Maccaferri M; Bettelli F; Luppi M; Cuneo A; Rossi G; Mecucci C
    Ann Hematol; 2022 Feb; 101(2):297-307. PubMed ID: 34859285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia.
    Jan M; Grinshpun DE; Villalba JA; Dal Cin P; Sykes DB; Iafrate AJ; Ebert BL; Hobbs GS; Nardi V
    Blood Adv; 2020 Feb; 4(3):445-448. PubMed ID: 31999327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.
    Abraham S; Salama M; Hancock J; Jacobsen J; Fluchel M
    Pediatr Blood Cancer; 2012 Nov; 59(5):928-9. PubMed ID: 22488677
    [TBL]